Departments of Pediatrics and of Social Preventive Medicine, University of Montreal, Montreal, Quebec, Canada.
Paediatr Respir Rev. 2011 Sep;12(3):170-6. doi: 10.1016/j.prrv.2011.02.007.
Oral corticosteroids are the cornerstone of management of acute moderate or severe asthma whilst preventive inhaled corticosteroids are the mainstay of the preventive management of children with asthma. Yet, variation in the magnitude of response to corticosteroids has been observed. There is increasing evidence that preschool-aged children with viral-induced asthma may display a certain degree of corticosteroid resistance, requiring higher doses of corticosteroids to overcome it. The identification of determinants of responsiveness is complicated by design issues, including heterogeneous populations of children with asthma and bronchiolitis or of children with viral-induced and multi-trigger asthma phenotypes in published trials. Potential key determinants of responsiveness may include age, trigger, phenotype, tobacco smoke exposure and genotype. The mechanistic pathway for corticoresistance may originate from a gene-environment interaction, leading to non-eosinophilic airway inflammation. The clinician should carefully confirm the diagnosis of asthma and ascertain the phenotype to select appropriate phenotype-specific therapy.
口服皮质类固醇是治疗急性中度或重度哮喘的基石,而预防吸入皮质类固醇则是预防儿童哮喘的主要方法。然而,皮质类固醇反应的程度存在差异。越来越多的证据表明,病毒性哮喘的学龄前儿童可能表现出一定程度的皮质类固醇抵抗,需要更高剂量的皮质类固醇才能克服。由于设计问题,包括在已发表的试验中哮喘和细支气管炎或病毒性和多触发哮喘表型的儿童的异质人群,确定反应性的决定因素变得复杂。反应性的潜在关键决定因素可能包括年龄、诱因、表型、吸烟和基因型。皮质激素抵抗的机制途径可能源于基因-环境相互作用,导致非嗜酸性气道炎症。临床医生应仔细确认哮喘的诊断,并确定表型,以选择适当的表型特异性治疗。